美股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

Bayer A.G.

7.87

+0.20002.61%

成交量：46.39萬

成交額：365.19萬

市值：309.27億

市盈率：-8.77

高：7.93

開：7.82

低：7.79

收：7.67

資料載入中...

總覽公司新聞公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞

拜耳(BAYRY)的前列腺癌藥物獲FDA批准

拜耳(BAYRY.US)宣佈Sevabertinib獲FDA優先審評用於治療HER2突變NSCLC

拜耳第四季度每股收益調整值為$0.28，低於$1.00的預期，銷售額為$125.2億，高於$113.0億的預期

拜耳(BAYRY.US)非奈利酮片新適應症在華上市申請獲理

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BAYRY"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BAYRY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","market":"US","secType":"STK","nameCN":"Bayer A.G.","latestPrice":7.87,"timestamp":1751054400000,"preClose":7.67,"halted":0,"volume":463934,"delay":15,"floatShares":3929259738,"shares":3929696328,"eps":-0.897103,"marketStatus":"休市中","change":0.2,"latestTime":"06-27 16:00:00 EDT 延時","open":7.82,"high":7.93,"low":7.79,"amount":3651859.3794000074,"amplitude":0.018253,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.897103,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1751270400000},"marketStatusCode":7,"adr":0,"adrRate":0.25,"exchange":"OTCQX","adjPreClose":7.67,"volumeRatio":0.8578880156652624},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BAYRY\",,,,,undefined,":{"symbol":"BAYRY","floatShares":3929259738,"roa":"2.55%","roe":"-9.49%","lyrEps":-0.672343,"volumeRatio":0.8578880156652624,"shares":3929696328,"dividePrice":0.030365,"high":7.93,"amplitude":0.018253,"preClose":7.67,"low":7.79,"week52Low":4.79,"pbRate":"0.81","psRate":"0.57","week52High":8.58,"institutionHeld":0,"latestPrice":7.87,"eps":-0.897103,"divideRate":0.003858,"volume":463934,"delay":15,"ttmEps":-0.897103,"open":7.82,"prevYearClose":4.88,"prevWeekClose":7.68,"prevMonthClose":7.07,"prevQuarterClose":6.02,"fiveDayClose":7.68,"twentyDayClose":7.06,"sixtyDayClose":6.05},"@#url:\"https://hq.skytigris.cn/market/plate/belongs/BAYRY\",params:#limit:6,delay:false,,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BAYRY\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2540067388","title":"拜耳(BAYRY)的前列腺癌藥物獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2540067388","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2540067388?lang=zh_tw&edition=fundamental","pubTime":"2025-06-04 23:17","pubTimestamp":1749050236,"startTime":"0","endTime":"0","summary":"金吾财讯 | 拜耳(BAYRY)表示，其药物Nubeqa已获得美国食品药品管理局(Food and Drug Administration)的批准；该药物用于治疗患有特定类型前列腺癌的患者。这家德国生命科学公司表示，此番批准是基于一项3期试验的积极结果。相关试验结果显示，在接受Nubeqa联合另一种疗法治疗的患者中，发生影像学进展或死亡的风险降低了46%。","market":"sg","thumbnail":"https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/ZDhjMmEyODE0Mjk1MzY2MjA4.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"289171","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY","BK4007"],"gpt_icon":0},{"id":"2539226378","title":"拜耳(BAYRY.US)宣佈Sevabertinib獲FDA優先審評 用於治療HER2突變NSCLC","url":"https://stock-news.laohu8.com/highlight/detail?id=2539226378","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2539226378?lang=zh_tw&edition=fundamental","pubTime":"2025-05-29 21:20","pubTimestamp":1748524808,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月28日，拜耳(BAYRY.US)宣布Sevabertinib(BAY 2927088)获FDA授予优先审评资格，用于治疗已经接受过一种系统治疗的HER2突变非小细胞肺癌患者。Sevabertinib为拜耳的核心管线之一，此前已经获得中国、美国的突破疗法认证，目前正在推进三期验证性临床SOHO-02，以及HER2激活突变泛瘤种的二期临床panSOHO。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1299369.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拜耳(BAYRY.US)宣布Sevabertinib获FDA优先审评 用于治疗HER2突变NSCLC","news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BAYRY"],"gpt_icon":0},{"id":"1154866640","title":"拜耳第四季度每股收益調整值為$0.28，低於$1.00的預期，銷售額為$125.2億，高於$113.0億的預期","url":"https://stock-news.laohu8.com/highlight/detail?id=1154866640","media":"财报速递","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154866640?lang=zh_tw&edition=fundamental","pubTime":"2025-03-05 19:19","pubTimestamp":1741173549,"startTime":"0","endTime":"0","summary":"拜耳公布的季度每股收益为$0.28，较分析师一致预期的$1.00低出72%，与去年同期的每股收益$0.50相比下降了44%。以上内容来自Benzinga Earnings专栏，原文如下：Bayer  reported quarterly earnings of $0.28 per share which missed the analyst consensus estimate of $1.00 by 72 percent. This is a 44 percent decrease over earnings of $0.50 per share from the same period last year.  The company reported quarterly sales of $12.52 billion which beat the analyst consensus estimate of $11.30 billion by 10.81 percent.  This is a 1.96 percent decrease over sales of $12.77 bi","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"拜耳第四季度每股收益调整值为$0.28，低于$1.00的预期，销售额为$125.2亿，高于$113.0亿的预期","news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BAYRY"],"gpt_icon":1},{"id":"2505632885","title":"拜耳(BAYRY.US)非奈利酮片新適應症在華上市申請獲理","url":"https://stock-news.laohu8.com/highlight/detail?id=2505632885","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505632885?lang=zh_tw&edition=fundamental","pubTime":"2025-01-24 14:38","pubTimestamp":1737700694,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，1月24日，中国国家药监局药品审评中心官网最新公示，拜耳非奈利酮片的新适应症上市申请获得受理。具体而言，试验结果显示，在LVEF≥40%的心力衰竭患者中，非奈利酮将心血管死亡和总心力衰竭事件构成的复合临床指标降低16%，达成试验主要终点。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1243237.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"拜耳(BAYRY.US)非奈利酮片新适应症在华上市申请获理","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4007","BAYRY"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":4,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/BAYRY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-05-13","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1747108800000,"reportTimeType":"","actualEps":null},{"date":"2025-04-29","symbol":"BAYRY","amount":0.030365,"announcedDate":"2025-04-04","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-04-29","defaultRemindTime":1745933400000,"name":"Bayer A.G.","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-05-12","payableDate":"2025-04-29","currency":"USD","dateTimestamp":1745899200000,"payDate":"2025-05-12"},{"market":"US","date":"2024-11-12","symbol":"BAYRY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1731387600000,"reportTimeType":"","actualEps":null},{"date":"2024-08-06","symbol":"BAYRY","type":"earning","reportTimeType":"post","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1722974400000,"name":null,"time":"盤後","dateTimestamp":1722916800000,"actualEps":null},{"date":"2024-05-14","symbol":"BAYRY","type":"earning","reportTimeType":"","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"","dateTimestamp":1715659200000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"BAYRY\",market:\"US\",,,undefined,":[{"executeDate":"2016-04-27","recordDate":"2016-04-29","paymentDate":"2016-05-12","value":2.091196,"currency":"USD"},{"executeDate":"2019-04-29","recordDate":"2019-04-30","paymentDate":"2019-05-13","value":0.550569,"currency":"USD"},{"executeDate":"2020-04-29","recordDate":"2020-04-30","paymentDate":"2020-05-14","value":0.535933,"currency":"USD"},{"executeDate":"2021-04-28","recordDate":"2021-04-29","paymentDate":"2021-05-10","value":0.407111,"currency":"USD"},{"executeDate":"2022-05-02","recordDate":"2022-05-03","paymentDate":"2022-05-16","value":0.549114,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"BAYRY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.5,"buy":0,"hold":0.5,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0,"analysts":2,"updateTime":1746244800000}}}